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Abstract 
Background: A20 is a dual inhibitor of NF-κB activation and apoptosis in the tumor necrosis factor receptor 1 signal-
ing pathway, and both are related to tumorigenesis. A20 is frequently inactivated by deletions and/or mutations in 
several B and T cell lymphoma subtypes; however, knowledge of the role of A20 in B-cell acute lymphoblastic leuke-
mia (B-ALL) remains limited. In this study, we characterized the A20 gene expression pattern, the expression level of its 
upstream regulating factor MALT1, and its downstream target NF-κB in adult B-ALL.
Methods: The expression level of MALT1, A20 and NF-κB1 was detected in peripheral blood mononuclear cells 
(PBMCs) from 20 patients with adult B-ALL (including 12 de novo B-ALL and 8 refractory/relapse B-ALL cases), and 
nine patients with B-ALL in complete remission (CR) using real-time PCR. Sixteen healthy individuals served as 
controls.
Results: Significant A20 overexpression was found in the B-ALL (median: 13.489) compared with B-ALL CR (median: 
3.755) (P = 0.003) patients and healthy individuals (median: 8.748) (P = 0.002), while there was no significant differ-
ence in A20 expression between B-ALL CR patients and healthy individuals (P = 0.107). Interestingly, the A20 expres-
sion level in the B-ALL samples was relatively different with approximately 50% of the B-ALL cases showing a relatively 
high A20 expression level, while the remaining 50% cases demonstrated slight upregulation or a similar expression 
level as the healthy controls. However, there was no significant difference in the A20 expression level between de 
novo B-ALL (median 12.252) and refractory/relapse B-ALL patients (median 21.342) (P = 0.616). Similarly, a significantly 
higher expression level of NF-κB1 was found in the B-ALL (median 1.062) patients compared with healthy individuals 
(median 0.335) (P < 0.0001), while the NF-κB1 expression level was downregulated in the B-ALL CR group (median 
0.339), which was significantly lower than that in those with B-ALL (P = 0.001). Moreover, the MALT1 expression level 
in B-ALL was upregulated (median 1.938) and significantly higher than that in healthy individuals (median 0.677) 
(P = 0.002) and B-ALL CR patients (median 0.153) (P = 0.008). The correlation of the expression levels of all three 
genes was lost in B-ALL.
Conclusions: We found that MALT1-A20-NF-κB is overexpressed in adult B-ALL, which may be related to the patho-
genesis of B-ALL, and this pathway may be considered a potentially attractive target for the development of B-ALL 
therapeutics.
Keywords: B-cell acute lymphoblastic leukemia, A20, MALT1, NF-κB
© 2015 Xu et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Adult B-cell acute lymphoblastic leukemia (B-ALL) 
results from clonal malignant B-cell proliferation arising 
from genetic alterations that block lymphoid differen-
tiation and drive aberrant cell proliferation and survival. 
B-ALL is the most common hematologic malignancy 
in children. The cure rate for B-ALL in children is 80%, 
while it is less than half in adults. Some genetic markers 
for B-ALL have been found to have prognostic impact [1]. 
Although great strides have been made toward improving 
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B-ALL outcome, the prognosis for disease relapse has 
significantly lagged behind, particularly for adults with 
B-ALL. Understanding the underlying genomic lesions 
and epigenetic regulatory mechanisms associated with 
leukemic transformation, drug resistance and disease 
relapse is essential to revolutionizing leukemia care in 
this era of personalized medicine. Recently, advances in 
cytogenetics utilizing array-based technologies and next-
generation sequencing (NGS) have revealed exciting 
insights into the genetic basis of B-ALL [2–6].
A20 (also known as TNFAIP3) is a cytoplasmic pro-
tein that was first identified as a tumor necrosis factor 
(TNF) primary response transcript encoding a 790 amino 
acid protein with a unique zinc finger motif [7]. The 
C-terminal domain of A20 (residues 427–790) is critical 
for its modulation of NF-κB, while its N-terminal deu-
biquitinase domain may promote the de-ubiquitination 
of K63-polyubiquitin chains. A number of studies have 
indicated that A20 is a potent anti-inflammatory signal-
ing molecule that restricts multiple intracellular signaling 
cascades and the importance of A20-mediated regulation 
of ubiquitin-dependent signaling in autoimmune diseases 
and cancer [8, 9].
Thus, A20 play crucial physiological roles as a dual 
inhibitor of NF-κB activation and apoptosis in the tumor 
necrosis factor (TNF) receptor 1 signaling pathway. A20 
inactivation results in constitutive NF-κB activation, and 
it is linked to autoimmune and malignant disease, par-
ticularly for B-cell lymphomas. In B-cell lymphoma, A20 
is thought to act as a tumor suppressor because consti-
tutive NF-κB activation has been implicated in tumo-
rigenesis. As a negative regulator of NF-κB, A20 plays 
a pivotal role in the regulation of the immune response 
and prevents excessive NF-κB activation in response to 
a variety of external stimuli. Recent genetic studies have 
shown that A20 is a common genetic target in B-lineage 
lymphomas. A20 is frequently inactivated by somatic 
mutations and/or deletions in different subtypes of B-cell 
non-Hodgkin lymphomas, Hodgkin’s lymphoma, and 
T-cell malignancy-Sézary syndrome (SS). Moreover, A20 
promoter methylation is also frequently detected in these 
lymphomas. When wild-type A20 was re-expressed in a 
lymphoma-derived cell line, there was cell growth sup-
pression and the induction of apoptosis accompanied 
by the downregulation of NF-κB activation, while down-
regulation of A20 expression by siRNA in Epstein-Barr 
virus-infected lymphoblastoid cell lines was associated 
with apoptosis resistance and enhanced clonogenicity. 
Overall, the uncontrolled NF-κB signaling caused by a 
loss in A20 function is involved in the pathogenesis of 
subsets of B-lineage lymphomas [10–14].
In contrast, A20 was initially identified as a primary 
gene product following TNFα treatment in human 
umbilical vein endothelial cells, and it has been shown 
to inhibit TNF-induced apoptosis. It was also shown that 
A20 has an anti-apoptotic function via the suppression of 
c-jun N-terminal kinase (JNK) by targeting apoptosis sig-
nal-regulating kinase1 (ASK1) [15]. A20 has been found 
to have antiapoptotic function in several cancer cells, its 
increased expression is associated with tumorigenesis, 
and it is involved in drug resistance in many cancers, 
such as glioblastomas, breast cancer, hepatocellular car-
cinoma, and nasopharyngeal carcinoma (NPC) [16–21]. 
For example, A20 has been shown to protect MCF-7 
breast carcinoma cells from TNFα-induced apoptosis. 
In addition, high A20 expression levels were observed 
in more aggressive breast tumors (ER-negative, proges-
terone receptor-negative and high histological grade). 
Furthermore, A20 is a key protein involved in tamoxifen 
resistance [20]. A20 is overexpressed in glioblastoma 
stem cells, and inhibiting A20 expression by targeting 
its mRNA with short hairpin RNAs decreases glioblas-
toma stem cell growth and survival, and the tumorigenic 
potential of treated glioblastoma stem cells decreases, 
resulting in increased survival of mice bearing human 
glioma xenografts [22]. In this scenario, A20 is thought to 
be an oncogene.
Inactivating mutations of A20 in lymphoma suggest 
that A20 can act as a tumor suppressor; however, similar 
point mutations in A20 may function as tumor enhanc-
ers in glioma via the promotion of glioblastoma stem 
cell survival [22]. Although it is known that A20 has dual 
functions and both are related to tumorigenesis, why 
and what function A20 plays in different cancers remain 
largely unknown. In this study, we characterized the gene 
expression pattern of A20 and the gene expression level 
of the upstream regulating factor MALT1 and its target 
NF-κB in adult B-ALL.
Methods
Samples
The samples used in this study were derived from 20 
cases with adult B-ALL, including 12 newly diagnosed 
cases, untreated patients with B-ALL (7 males and 5 
females; 17–72  years old, median age: 27.0  years) and 
eight cases with refractory/relapse B-ALL (3 males and 
5 females; 16–59  years old, median age: 30.5  years). 
The clinical information of the B-ALL cases is listed 
in Table  1. Nine cases with adult B-ALL in complete 
remission (CR) (6 males and 3 females; 17–56 years old, 
median age: 28.0 years) were analyzed in this study. Six-
teen healthy individuals including 10 males and 6 females 
(17–45  years old, median age: 26  years) served as con-
trols. Peripheral blood mononuclear cells (PBMCs) were 
isolated from heparinized venous blood by Ficoll-Paque 
gradient centrifugation. RNA extraction and cDNA 
Page 3 of 8Xu et al. Cancer Cell Int  (2015) 15:73 
synthesis from PBMCs were performed according to the 
manufacturer’s instructions. All human peripheral blood 
samples were obtained with consent. All procedures were 
conducted according to the guidelines of the Medical 
Ethics Committee of the Health Bureau of Guangdong 
Province in China, and ethical approval was obtained 
from the Ethics Committee of the Medical School of 
Jinan University.
Quantitative real‑time RT‑PCR (qRT‑PCR)
The primers used in this study for MALT1, A20 and 
NF-κB1 gene amplification were previously described 
(Table  1) [23–25]. The expression level of the MALT1, 
A20, NF-κB1 and β2-microglobulin (β2M) genes was 
determined by SYBR Green I real-time RT-PCR as pre-
viously described [23, 24, 26, 27]. The relative amounts 
of the genes of interest and the β2M reference gene were 
measured in two independent assays. The specific ampli-
fied PCR products were analyzed by melting curve analy-
sis. The data are presented as the relative expression of 
the genes of interest compared with the internal con-
trol gene as determined by the 2(−∆CT) method [23, 24, 
28–31].
Statistical analysis
Two independent-samples Wilcoxon tests were per-
formed to compare the median expression level of the 
A20, MALT1 and NF-κB1 genes among patients with 
B-ALL and B-ALL CR and healthy individuals. Spear-
man’s correlation and linear regression analyses were 
used to determine the association between different 
genes in different groups. A P < 0.05 was considered sta-
tistically significant [23, 24, 28, 29].
Results and discussion
A20 is a potent anti-inflammatory signaling molecule 
that restricts multiple intracellular signalling cas-
cades. A20 deficiency results in hyperactivity and loss 
of immune homeostasis in B cells. Recent studies have 
converged to highlight the clinical and biological impor-
tance of A20. Polymorphisms and mutations in the A20 
gene are linked to various human autoimmune condi-
tions and malignant diseases, and A20 inactivation is a 
frequent event in human B-cell lymphomas character-
ized by constitutive NF-κB activity, which is a major hall-
mark of B-cell malignancies. NF-κB-dependent genes are 
involved in anti-apoptosis, cell proliferation and metasta-
sis and are responsible for the survival and proliferation 
of tumors. Moreover, biochemical studies have unveiled 
complex mechanisms by which A20 regulates ubiquitin-
dependent NF-κB and cell-survival signals [8]. Although 
a number of reports have shown that A20 is frequently 
inactivated by deletions and/or mutations in several lym-
phoma subtypes [10–14, 32, 33], little is known about the 
role of A20 in B-ALL. In this study, we compared the A20 
expression level in PBMCs from patients with B-ALL 
(including de novo and refractory/relapse), patients with 
B-ALL in complete remission (CR) and healthy indi-
viduals. Significant overexpression of A20 was found 
in B-ALL (median 13.489) compared with B-ALL CR 
patients (median 3.755) (P = 0.003) and healthy individu-
als (median 8.748) (P =  0.002), while there was no sig-
nificant difference in A20 expression between B-ALL CR 
patients and healthy individuals (P = 0.107) (Figure 1a). 
Interestingly, the A20 expression level in B-ALL samples 
was relatively different with approximately 50% of the 
B-ALL patients showing a relatively high A20 expression 
level, while the remaining 50% showed slight upregula-
tion or a similar expression level as the healthy controls. 
We next examined whether the high expression level 
was related to disease status. We compared the expres-
sion level of A20 in newly diagnosed, untreated (de novo) 
B-ALL patients (median 12.252) and those with refrac-
tory/relapse B-ALL (median 21.342) (P  =  0.616) and 
found no significant difference. Moreover, not only was 
a relatively high A20 expression level found in approxi-
mately 50% of the cases with refractory/relapse B-ALL, 
it was also found in 30% of cases with newly diagnosed 
B-ALL (Figure  1b). Therefore, it appears that the A20 
expression level may not be related to disease status. This 
result is similar to a finding in pancreatic cancer reported 
by Wang et  al. who showed that low A20 expression is 
significantly associated with pancreatic cancer behav-
ior, but it is not the sole determinant of pancreatic can-
cer progression; A20 expression was not significantly 
associated with tumor grade, gender, age or TNM stage 
[26]. We further analyzed the association between the 
expression level of A20 and the percentage of B-ALL 
blasts in peripheral blood (Table  2). However, the per-
centage of B-ALL blasts was relatively variable in differ-
ent samples, and they did not appear to be significantly 
Table 1 The primers of quantitative real-time RT-PCR [23–
25]
Primer Sequence Accession no.
A20 For 5′-CTGGGACCATGGCACAACTC-3′ NM_006290
A20 Rev 5′-CGGAAGGTTCCATGGGATTC-3′
MALT1 For 5′-TCTTGGCTGGACAGTTTGTGA-3′ NM_006785.2
MALT1 Rev 5′-GCTCTCTGGGATGTCGCAA-3′
NF-κB1 For 5′-CCACAAGACAGAAGCTGAAG-3′ NM_003998
NF-κB1 Rev 5′-AGATACTATCTGTAAGTGAACC-3′
β2M For 5′-TACACTGAATTCACCCCCAC-3′ J00105
β2M Rev 5′-CATCCAATCCAAATGCGGCA-3′
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associated with the blast percentage and A20 expres-
sion level in each sample (r = −0.023, P = 0.922). Thus, 
it would be interesting to detect A20 protein expression 
in each blast cell. And it is about 50% of B-ALL patients 
with lower white blood cells (WBC) counts compared 
to the rest of the patients in the same group, so we fur-
ther analyzed the correlation between WBC counts and 
A20 expression levels to investigate whether the WBC 
count variation might have an impact on the difference 
of A20 expression detected in the B-ALL patients (Addi-
tional file 1: Table S1). However, the WBC counts did not 
shown significantly associated with the A20 expression 
levels in each group (P > 0.05).
It is known that A20 is a ubiquitin-editing enzyme 
with several functions. A20 was initially described as an 
inhibitor of TNF-induced cell death [34], and subsequent 
studies have demonstrated that A20 overexpression 
inhibits NF-κB activation in response to different stimuli 
Figure 1 A20 expression in peripheral blood mononuclear cells from patients with B-ALL and healthy individuals. a Comparison of the expression 
level of A20 in the B-ALL, B-ALL CR and healthy individual (HI) groups; b comparison of the expression level of A20 in the de novo B-ALL and refrac-
tory/relapse B-ALL groups.
Table 2 Clinical data of the B-ALL patients
C1 to C20 B-ALL case 1 to 20, M male, F female, WBC white blood cell, Hb hematoglobin.
No. Clinical stage Sex Age WBC (×109/L) Blast cells (%) Hb Platelets 
(×109/L)
C1 De novo M 31 3.49 94 111 10
C2 De novo M 71 7.99 17.3 83 118
C3 De novo M 28 41.9 91.9 104 15
C4 De novo M 31 7.68 71 110 28
C5 De novo F 16 62.3 95 76 24
C6 De novo M 16 144.7 63 68 76
C7 De novo F 72 17.44 82 93 20
C8 De novo F 18 33.92 60 58 4
C9 De novo F 17 2.5 59 106 29
C10 De novo M 38 29.54 82 53 41
C11 De novo F 20 4.5 86 57 8
C12 De novo M 26 27.5 88 49 24
C13 Refractory/relapse M 26 13.3 41 113 69
C14 Refractory/relapse F 16 18.68 33.8 98 93
C15 Refractory/relapse F 47 10.57 82.5 86 15
C16 Refractory/relapse M 40 4.75 41.5 79 74
C17 Refractory/relapse F 31 11.2 3.5 105 110
C18 Refractory/relapse F 30 61.6 54.5 108 197
C19 Refractory/relapse M 17 3.84 57 121 39
C20 Refractory/relapse F 59 2.48 18 81 28
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[8, 35, 36]. Stable overexpression of A20 in a number of 
cell lines, such as human breast carcinoma MCF7 cells 
and murine fibrosarcoma WEHI164 cells, was shown to 
result in partial resistance to TNF-induced apoptosis [14, 
32]. It should be noted that A20-mediated apoptosis inhi-
bition has not been observed in all of the cell lines stud-
ied. For example, A20 overexpression in human cervical 
carcinoma HeLa cells, lung epithelial A549 cells, and 
human hepatoma HepG2 cells had no effect on apopto-
sis induced by the Fas receptor, lymphokine-activated 
killer cells, serum depletion, or oxidative stress [14, 32]. 
Moreover, A20 deletions and mutations are frequent in 
lymphoma, and its function as a crucial tumor suppres-
sor and its deletion is closely associated with lymphoma 
[37]. The reason why some cell lines are protected by A20 
but others are not remains unclear. Unlike a finding in 
T-ALL in which significantly lower A20 expression was 
identified [23], we found overexpression of A20 in B-ALL 
and its reduced expression in B-ALL CR. Thus, it appears 
that the roles of A20 are different in B-ALL in which it 
may be an inhibitor of apoptosis rather than tumor sup-
pressor. A similar finding was reported by Frenzel et  al. 
who showed neither mutations nor aberrant DNA meth-
ylation for A20 in 55 cases with CLL and concluded that 
CLL malignant development differs from most other 
B-cell malignancies, which show frequent A20 inactiva-
tion [34]. However, the function of A20 needs to be fur-
ther investigated in B-ALL.
We also analyzed the expression level of NF-κB1, 
and a significantly higher expression level was found 
in patients with B-ALL (median 1.062) compared with 
healthy individuals (median 0.335) (P < 0.0001), while the 
NF-κB1 expression level was downregulated in B-ALL 
CR patients (median 0.339), which was significantly 
lower than that in the B-ALL group (P = 0.001) but simi-
lar to that of healthy individuals (P = 0.671) (Figure 2a). 
Although the NF-κB1 expression level appeared to be 
slightly high in de novo B-ALL patients (median 1.337) 
compared with those in the refractory/relapse B-ALL 
group (median 0.875), the difference was not significant 
(P = 0.114) (Figure 2b). In addition, the NF-κB1 expres-
sion level in both groups was significantly higher than 
that of healthy controls (P  =  0.0003 and P  <  0.0001, 
respectively) and B-ALL CR patients (P  =  0.003, 
P = 0.008). Higher NF-κB1 levels are characteristic of cell 
activation and is common in cancer cells; thus, our find-
ings are consistent with previous results [23, 34]. In fact, 
this finding is relatively supported by Wang et  al. who 
demonstrated that A20 is positively correlated with the 
tumorigenesis of bladder polypoid disorders [21].
We further analyzed the expression characteristics of 
MALT1, which positively regulated NF-κB1 as expected. 
MALT1 overexpression was found in the B-ALL group 
(median 1.938), and it was significantly higher than that 
in the healthy (median 0.677) (P = 0.002) and B-ALL CR 
groups (median 0.153) (P = 0.008), but its expression in 
healthy individuals and B-ALL CR patients had no sig-
nificant difference (P =  0.380) (Figure 3a). Interestingly, 
similar to the A20 expression profile, the MALT1 expres-
sion level in B-ALL samples was relatively different, par-
ticularly in de novo B-ALL patients (median 1.684), and 
it appeared to be slightly upregulated in comparison with 
those in the refractory/relapse B-ALL group (median 
2.096); however, the difference was not significant 
(P = 0.787) (Figure 3b).
MALT1 has proteolytic activity and controls lympho-
cyte activation by regulating NF-κB pathways, and it 
mediates rapid proteolytic cleavage and A20 inactiva-
tion [38]. Pathological alterations in the MALT1 pathway 
were identified in several subtypes of B-cell lympho-
mas, such as activated B-cell-like diffuse large B-cell 
lymphoma (ABC-DLBCL) [37]. In this study, MALT1 
Figure 2 NF-κB1 expression in peripheral blood mononuclear cells from patients with B-ALL and healthy individuals. a Comparison of the expres-
sion level of NF-κB1 in the B-ALL, B-ALL CR and healthy individual (HI) groups; b comparison of the expression level of NF-κB1 in the de novo B-ALL 
and refractory/relapse B-ALL groups.
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overexpression was suggested to mediate abnormal 
B-ALL cell activation. Unlike in T-ALL where we found 
significantly lower A20 expression with higher MALT1, 
suggesting that MALT1 might mediate A20 downregula-
tion [23], in this study, we found that both MALT1 and 
A20 were overexpressed. Combined with the NF-κB1 
results, these data suggested that A20 might play an 
oncogenic function in B-ALL, which was similar to its 
role in several cancers, such as glioblastomas, breast can-
cer, hepatocellular carcinoma, and nasopharyngeal carci-
noma (NPC) [16, 18–21].
Overall, we demonstrated that significant overexpres-
sion of MALT1, A20 and NF-κB1 in B-ALL samples 
may be related to the abnormal proliferation of malig-
nant B cells. Moreover, we found that the correlations 
of the expression levels of the three genes were lost 
in B-ALL samples because the A20 expression level is 
negatively correlated with that of MALT1 (r = −0.8601, 
P < 0.0001) and NF-κB1 (r = −0.9059, P < 0.0001), and 
the expression levels of MALT1 and NF-κB1 (r = 0.7786, 
P = 0.0004) are positively correlated in healthy individu-
als [23]. However, we also found a higher expression level 
for A20 accompanied by a higher expression level for 
MALT and/or NF-κB1, particularly in de novo B-ALL 
samples (Figure 4). This observation led us to ask whether 
there are two B-ALL subtypes based on the MALT1-A20-
NF-κB expression pattern, and such abnormal expression 
characteristics may be considered biomarkers for target 
factors in B-ALL.
Like some epitopes on the lymphoma surface have been 
identified as potential targets for monoclonal antibodies 
[39], overexpressed genes may be considered potentially 
attractive targets for the development of B-ALL thera-
pies. In the clinical, it is well known that NF-κB is a target 
Figure 3 MALT1 expression in peripheral blood mononuclear cells from patients with B-ALL and healthy individuals. a Comparison of the expres-
sion level of MALT1 in the B-ALL, B-ALL CR and healthy individual (HI) groups; b comparison the expression level of MALT1 in the de novo B-ALL and 
refractory/relapse B-ALL groups.
Figure 4 The association between the A20, NF-κB1 and MALT1 expression levels in de novo B-ALL samples. a A20 gene expression level; b NF-κB1 
gene expression level; c MALT1 gene expression level. Grey dots: C2, green dots: C3, blue dots: C5, red dots: C7, olive dots: C9, pink dots: C10.
Page 7 of 8Xu et al. Cancer Cell Int  (2015) 15:73 
for multiple myeloma therapy via proteasome inhibitors 
such as bortezomib [40]. Moreover, there are two types 
of small molecule inhibitors for MALT1 in preclinical 
studies. One inhibitor is the phenothiazine derivative 
mepazine, which has been shown to have promising anti-
cancer properties in B cell lymphoma subtypes [41]. The 
other inhibitor is MI-2, which directly binds to MALT1, 
and irreversibly suppresses its protease function and 
exhibits selective activity against ABC-DLBCL cell lines 
in vitro and ABC-DLBCL xenotransplant tumors in vivo. 
It may be worth investigating the anti B-ALL effects of 
such MALT1 inhibitors [42]. For A20 target inhibition, 
siRNA was used to downregulate A20, and greatly inhib-
iting A20 expression slowed tumor cell growth in culture 
and mice, and it was also shown to induce apoptosis in 
glioblastomas [19]. Moreover, current renewed apprecia-
tion of the unique molecular signatures of tumors holds 
promise for personalized chemotherapeutic regimens, 
hopefully comprising specific MALT1-A20-NF-κB path-
way-targeting agents [43].
Conclusions
Recent reports have indicated that A20 expression is 
increased in a number of solid human tumors [43]. In 
this study, we first demonstrated the overexpression and 
loss of the normal expression pattern of MALT1, A20, 
and NF-κB1 at the molecular level, indicating that their 
manner of regulation in B-ALL may be more complex. 
The altered MALT1-A20-NF-κB pathway may contribute 
to the pathogenesis of B-ALL, and this pathway may be 
considered a potentially attractive target for the develop-
ment of B-ALL therapeutics. However, these findings are 
based on results from a limited case analysis, and further 
study involving more samples is needed to determine 
representative results.
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